Brain, Vol. 124, No. 7, 1396-1402,
July 2001
© 2001 Oxford University Press
T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment
.
1 MR-MS centre, VU Medical Centre, Amsterdam, the Netherlands, 2 Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute San Raffaele, University of Milan, 3 Department of Neurology, La Sapienza, Rome, Italy, 4 Department of Neuroradiology, Klinikum Grosshadern, Munich, 5 Institut for Röntgendiagnostik, Universität Würzburg, Germany, 6 NMR Research Group, Institute of Neurology, London, UK and 7 Department of Neurology, University Hospitals, Kantonsspittal, Basel, Switzerland
Correspondence to:
Dr F. Barkhof, MS-MRI Centre and Department of Radiology, VU Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands E-mail: f.barkhof{at}azvu.nl
Recently, the clinical efficacy of interferon ß-1b (IFNß-1b) was demonstrated for secondary progressive (SP) multiple sclerosis in a European multicentre study. We evaluated the effect of IFNß-1b treatment on the rate of development of hypointense T1 MRI lesions, a putative marker of axonal damage. Unenhanced T1-weighted images were obtained in a subgroup of 95 multiple sclerosis patients from five centres at 6-month intervals; this subgroup was similar to the total study population for all demographic, clinical and MRI parameters. An experienced observer blinded to the clinical data and treatment allocation measured volumes. The median baseline lesion load for hypointense T1 lesions was 5.1 cm3 for placebo-treated and 4.9 cm3 for IFNß-1b-treated patients (P = 0.56). Placebo-treated patients showed an increase in T1 lesion load by a median of 14% per year (P = 0.0002 compared with baseline); this was reduced to 7.7% per year in the IFNß-1b-treated patients (P = 0.003 versus placebo). In the IFNß-1b arm there was a statistically significant correlation between absolute change in Expanded Disability Status Scale scores and T1 lesion load by month 36 (r = 0.38, P = 0.0015). In patients with SP multiple sclerosis, IFNß-1b treatment reduces the development of hypointense T1 lesions, suggesting that reduced axonal damage in lesions may play a part in the beneficial effect that is observed clinically.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Barkhof, C. H. Polman, E.-W. Radue, L. Kappos, M. S. Freedman, G. Edan, H.-P. Hartung, D. H. Miller, X. Montalban, P. Poppe, et al. Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results Arch Neurol, September 1, 2007; 64(9): 1292 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Naismith and A. H. Cross Multiple Sclerosis and Black Holes: Connecting the Pixels Arch Neurol, November 1, 2005; 62(11): 1666 - 1668. [Full Text] [PDF]
|
|
|
|
|
|
F. Bagnato, S. Gupta, N. D. Richert, R. D. Stone, J. M. Ohayon, J. A. Frank, and H. F. McFarland Effects of Interferon Beta-1b on Black Holes in Multiple Sclerosis Over a 6-Year Period With Monthly Evaluations Arch Neurol, November 1, 2005; 62(11): 1684 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Pulicken, C N Bash, K Costello, A Said, C Cuffari, J L Wilterdink, J M Rogg, P Mills, and P A Calabresi Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis Multiple Sclerosis, April 1, 2005; 11(2): 169 - 174. [Abstract] [PDF]
|
|
|
|
|
|
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials Multiple Sclerosis, August 1, 2004; 10(4): 341 - 347. [Abstract] [PDF]
|
|
|
|
|
|
L. Kappos Effect of drugs in secondary disease progression in patients with multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S46 - S55. [Abstract] [PDF]
|
|
|
|
|
|
L. Kappos Effect of drugs in secondary disease progression in patients with multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S46 - S55. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Bagnato, N. Jeffries, N. D. Richert, R. D. Stone, J. M. Ohayon, H. F. McFarland, and J. A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain, August 1, 2003; 126(8): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Inglese, J.H.T.M. van Waesberghe, M. Rovaris, K. Beckmann, F. Barkhof, D. Hahn, L. Kappos, D.H. Miller, C. Polman, C. Pozzilli, et al. The effect of interferon {beta}-1b on quantities derived from MT MRI in secondary progressive MS Neurology, March 11, 2003; 60(5): 853 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Brex, P. D. Molyneux, P. Smiddy, F. Barkhof, M. Filippi, T. A. Yousry, D. Hahn, Y. Rolland, O. Salonen, C. Pozzilli, et al. The effect of IFN{beta}-1b on the evolution of enhancing lesions in secondary progressive MS Neurology, December 26, 2001; 57(12): 2185 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Molyneux, G. J. Barker, F. Barkhof, K. Beckmann, F. Dahlke, M. Filippi, M. Ghazi, D. Hahn, D. MacManus, C. Polman, et al. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS Neurology, December 26, 2001; 57(12): 2191 - 2197. [Abstract] [Full Text] [PDF]
|
|